Find a Clinical Trial

Researching Blood Cancer

Blood cancers form in the bone marrow where blood is made, or in the lymphatic system, which protects us from infections.

Blood Cancer Clinical Trials

Blood Cancer Clinical Trials

We are currently investigating experimental medications for Multiple Myeloma, Lymphoma and Leukemia.

Multiple Myeloma is a type of blood cancer which forms in plasma cells.
Lymphomas are blood cancers that target the immune system.
Leukemia is a cancer of the blood and bone marrow caused by too many white blood cells, leukemia takes on several forms and can occur in both children and adults.

Thank you for Considering a Clinical Trial

Below you will find clinical trials that are either currently recruiting patients (noted as Recruiting) or starting to recruit patients soon (noted as Not Yet Recruiting).

Here are some options for you to find more information:

Browse the trials available on your own and Click on View Trial Details for more information, including locations that are recruiting patients.
- or -
Let us help you find a trial: Pre-Screen Now and answer a few questions to determine if there is a trial that might be right for you.

Blood Cancer Trials

CA204-008

Recruiting

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

View Trial Details

JCAR017-FOL-001

Recruiting

A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

Juno Therapeutics and Celgene are wholly owned subsidiaries of Bristol-Myers Squibb Company

View Trial Details

CC-99282-NHL-001

Recruiting

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

View Trial Details

CC-92480-MM-002

Recruiting

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

View Trial Details

ACE-536-MF-002

Recruiting

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

View Trial Details

CC-91633-AML-001

Recruiting

Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

View Trial Details

CC-92328-MM-001

Recruiting

Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

View Trial Details

CC-220-MM-002

Recruiting

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

View Trial Details

CA057-003

Recruiting

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

View Trial Details

CA055-026

Recruiting

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)

View Trial Details

CA059-001

Recruiting

A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes

View Trial Details

CA057-001

Recruiting

A Study to Evaluate CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

View Trial Details

CA057-008

Recruiting

A Study to Evaluate CC-92480 in Combination With Carfilzomib and Dexamethasone (480Kd) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

View Trial Details

CA092-1000

Recruiting

A Rollover Study of CC-122

View Trial Details

IM048-022

Recruiting

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

View Trial Details

CA056-025

Recruiting

ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions

View Trial Details

Explore Blood Cancer Resources

SELECTED SUPPORT ORGANIZATIONS AND DISEASE INFORMATION

Bristol Myers Squibb is not affiliated with nor endorses any of the listed organizations. The information/links provided by Bristol Myers Squibb are meant for informational purposes only and are not meant to replace a physician's medical advice or imply endorsement. This is not an exhaustive list of resources for this condition. There may be others that you may wish to explore.

Leukemia & Lymphoma Patient Resources The Leukemia & Lymphoma Society of Canada

Lymphoma Canada

Canadian CML Network

We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information

Have questions? Live support is available 24/7 - Call 833-673-6134 Or Email Us

Have questions? Live support is available 24/7 -

Call 833-673-6134 Or Email Us